APR 07, 2020 8:19 AM PDT

Second COVID-19 Vaccine Enters Human Trials

WRITTEN BY: Carmen Leitch

Yesterday, Inovio Pharmaceuticals, Inc. announced that it will begin human trials on a potential vaccine for COVID-19. The US Food and Drug Administration accepted its investigational drug application for the candidate vaccine, now called INO-4800, and the company will start injecting healthy volunteers in a Phase I trial as soon as this week.

Preclinical data obtained using various animal models have shown that the vaccine can initiate an immune response. Now, the company has to demonstrate that it triggers an immune response in people as well and that it is safe.

The Phase 1 trial will be enrolling around 40 healthy participants at one of two sites: the Perelman School of Medicine at the University of Pennsylvania in Philadelphia or the Center for Pharmaceutical Research in Kansas City, Missouri. Every volunteer is slated to receive two doses of the vaccine, one four weeks after the other. The company expects the results from the trial in late summer.

"We anticipate rapid enrollment of this initial study," said the Principal Investigator of the study Pablo Tebas, MD, an infectious disease specialist and professor of Medicine at the Hospital of the University of Pennsylvania. "There has been tremendous interest in this vaccine among people who want to do what they can to help protect the greater public from this pandemic as soon as possible."

Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. / Credit: NIAID

Their vaccine uses a small piece of DNA that is injected into the body (and is supposed to initiate an immune response). Like other vaccines, priming the immune system in this way gives the body a 'memory' of an infection so that if it does encounter the pathogen, it already has antibodies in place to fight it. DNA vaccines are used in veterinary medicine but have not yet been used in humans.

Inovio is supported by the Coalition for Epidemic Preparedness Innovations (CEPI) and the Bill and Melinda Gates Foundation. Bill Gates has said in a recent interview that his foundation is planning to pick seven top COVID-19 vaccine candidates and generate the infrastructure to manufacture all of them. Not every one will be a winner, he said two at most might make it to market, but this will rapidly accelerate the process by building a factory as the vaccine is being developed, instead of waiting until it's already been created to start construction.

If the trials produce good results, Inovio claims it can have up to one million vaccine doses ready for around the end of the year, which could be used in more trials or as emergencies required. It would take a few more months to have the vaccine ready for a wider rollout.

"This is a significant step forward in the global fight against COVID-19," said the President and CEO of Inovio,  Dr. J. Joseph Kim. "Without a new safe and effective vaccine, the COVID-19 pandemic is likely to continue to threaten lives and livelihoods. It also demonstrates the power of our DNA medicines platform to rapidly develop and advance a vaccine for COVID-19 into Phase 1 clinical testing. Our dedicated team of staff, partners and funders have been mobilized since the genetic sequence of the virus became available in early January and continues to work around the clock to ensure that we are rapidly advancing INO-4800 through this Phase 1 study towards planned efficacy trials."

Inovio also already has a little experience in this field. The company has previously completed a successful clinical trial that tested a vaccine for the coronavirus that causes MERS.

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
MAR 10, 2020
Microbiology
MAR 10, 2020
Study Suggests 14-Day Quarantine for SARS-CoV-2 is Reasonable
The vast majority (97.5%) of people will develop symptoms of infection within 11.5 days of exposure to the virus.
MAR 15, 2020
Microbiology
MAR 15, 2020
COVID-19 - What To Do If You Get Sick
It now seems that the SARS-CoV-2 virus is spreading through communities in many places worldwide.
MAR 18, 2020
Microbiology
MAR 18, 2020
The Coronavirus SARS-CoV-2 is Stable for Hours on Surfaces
SARS-CoV-2 is a coronavirus that causes an illness called COVID-19. There are now well over 210,000 confirmed cases worl ...
MAR 23, 2020
Genetics & Genomics
MAR 23, 2020
Diagnosing Cancer by Looking for Microbial DNA in the Blood
Liquid biopsies aim to diagnose a disease with only a bit of biological fluid, usually blood.
APR 20, 2020
Microbiology
APR 20, 2020
A Neuropsychiatric Crisis Might Follow COVID-19
Past pandemics have been accompanied by a rise in a variety of mental health and neurological problems.
MAY 10, 2020
Cell & Molecular Biology
MAY 10, 2020
RNA Structure Informs RNA Function
Proteins carry out many of an organism's critical functions, and they are coded for by genes. To make a protein from ...
Loading Comments...